UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **August 28, 2014**

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California	**1-12830**	**94-3127919**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1301 Harbor Bay Parkway
Alameda, California 94502
(Address of principal executive offices)

(510) 521-3390
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as "may, "will," "believes," "plans," "intends," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in BioTime's periodic reports filed with the SEC under the heading "Risk Factors" and other filings that BioTime may make with the Securities and Exchange Commission. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, BioTime disclaims any intent or obligation to update these forward-looking statements.

This Report and any accompanying exhibits shall be deemed "furnished" and not "filed" under the Securities Exchange Act of 1934, as amended.

Section 7 - Regulation FD

Item 7.01 - Regulation FD Disclosure

On August 28, 2014, BioTime, Inc. issued the press release furnished as Exhibit 99.1, which is incorporated by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release Dated August 28, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: August 28, 2014

By: /s/ Michael D. West
Chief Executive Officer

Exhibit Number	Description
99.1	Press Release Dated August 28, 2014.

Exhibit 99.1

BioTime to Collaborate With the University of Wisconsin and Louvain University in Test of *HyStem*®-Based Hydrogel for Vocal Fold Scarring

Investigator-initiated clinical trial may follow preclinical studies

ALAMEDA, Calif.--(BUSINESS WIRE)--August 28, 2014--BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime's proprietary *HyStem*®-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. Thibeault and her colleagues have demonstrated that localized delivery of *HyStem*® into injured vocal folds resulted in a significant improvement in function. Under a sponsored research agreement, Dr. Thibeault's laboratory will evaluate *HyStem*®-based hydrogels to identify formulations with optimum properties for reducing scarring. Upon completion of these preclinical studies, an investigator-initiated clinical trial in patients with vocal fold scarring due to disease or prior surgical interventions is planned, under the direction of Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in Belgium, subject to institutional and regulatory approval.

Background

Scarring of the vocal folds is the most common cause of undesired changes in the voice (dysphonia) following injury, disease, or surgical procedures. Current treatments are limited to microsurgical treatments including scar lysis/excision, medialization laryngoplasty, or engraftment of tissue flaps/grafts. Since the region of the vocal fold affected by scarring is rich in hyaluronic acid, nonclinical studies of *HyStem*®-based hydrogels have been performed which indicate that localized injection of a *HyStem*® hydrogel during surgical release of the adhesions provides an environment for improved tissue viscoelasticity vital for vocal fold function. Because vocal fold scarring remains one of the most challenging problems for otolaryngologists using the available technology, continued successful preclinical studies could lead to investigator-initiated clinical investigations, and efforts for regulatory approval for this indication.

"If products could be developed that would improve vocal fold healing with decreased scarring, it could have widespread clinical application for improved patient outcomes," said Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in Belgium.

"The expanded application of *HyStem*® hydrogels in the field of vocal fold disorders, is just one example of the breadth of potential applications of the technology," said Dr. William Tew, BioTime's Chief Commercial Officer. "Our numerous academic collaborations play an important role in advancing these novel applications in medicine. For example, we are seeing numerous scientific publications utilizing *HyStem*® technology in stem cell transplantation in the central nervous system, heart, liver, skin, orthopedic, and other tissues. We plan additional collaborations to further expand the breadth of uses of *HyStem*® technology as part of our strategy to aggressively commercialize this platform."

About HyStem®

BioTime's *HyStem®* family of hydrogels are unique biomaterials that are designed as matrices and scaffolds in medical device, tissue engineering, and regenerative medicine applications. *HyStem®* hydrogels are distributed and sold worldwide by BioTime and its distributors for pre-clinical research. *Renevia*™ is an injectable *HyStem®* hydrogel, for which clinical studies in Europe are scheduled for the purpose of evaluating *Renevia*™ as a delivery matrix for autologous adipose cells to treat the facial lipoatrophy associated with HIV. *Premvia*™ is a recently FDA-cleared medical device indicated for the management of wounds. Clinical grade hydrogels are also available to support translational research and investigator initiated clinical studies. BioTime's *HyStem®* technology is covered by two issued US patents with applications pending in the EU, Canada, Japan, and Australia.

About BioTime

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime's focus is on pluripotent stem cell technology based on human embryonic stem ("hES") cells and induced pluripotent stem ("iPS") cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime's therapeutic and research products include a wide array of proprietary *PureStem®* progenitors, *HyStem®* hydrogels, culture media, and differentiation kits. BioTime is developing *Renevia*™ (a *HyStem®* product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around *Renevia*™, in 2014. The *HyStem®*-based product *Premvia™* is cleared the FDA in the US for use in wound management. In addition, BioTime has developed *Hextend®*, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. *Hextend®* is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

- **Asterias Biotherapeutics**, Inc. is developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 oligodendrocyte progenitor cells in spinal cord injury, multiple sclerosis and stroke, and AST-VAC2, an allogeneic dendritic cell-based cancer vaccine. Asterias Series A common stock is traded under the symbol ASTY.
- **BioTime Asia**, Ltd., a Hong Kong company, may offer and sell products for research use for BioTime's ESI BIO Division.
- **Cell Cure Neurosciences** Ltd. is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis.
- **ESI BIO** is the research and product marketing division of BioTime, providing stem cell researchers with products and technologies to enable them to translate their work into the clinic, including *PureStem®* progenitors and *HyStem®* hydrogels.
- **LifeMap Sciences**, Inc. markets, sells, and distributes *GeneCards®*, the leading human gene database, as part of an integrated database suite that also includes the *LifeMap Discovery®* database of embryonic development, stem cell research, and regenerative medicine, and *MalaCards*, the human disease database.
- **LifeMap Solutions**, Inc. is a subsidiary of LifeMap Sciences focused on developing mobile health (mHealth) products.
- **OncoCyte** Corporation is developing products and technologies to diagnose and treat cancer, including *PanC-Dx*™, with three clinical trials currently underway.
- **OrthoCyte** Corporation is developing therapies to treat orthopedic disorders, diseases and injuries.
- **ReCyte Therapeutics**, Inc. is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.

BioTime stock is traded on the NYSE Market exchange, ticker BTX. For more information, please visit *www.biotimeinc.com* or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned

in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com

CONTACT:
BioTime, Inc.
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com